Rapid improvement after starting elexacaftor–tezacaftor–ivacaftor in patients with cystic fibrosis and advanced pulmonary disease

…, C Marguet, M Reynaud-Gaubert, J Macey… - American journal of …, 2021 - atsjournals.org
Rationale: Elexacaftor–tezacaftor–ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane
conductance regulator) modulator combination, developed for patients with CF with at least …

Quiet submillimeter MR imaging of the lung is feasible with a PETRA sequence at 1.5 T

G Dournes, D Grodzki, J Macey, PO Girodet, M Fayon… - Radiology, 2015 - pubs.rsna.org
Purpose To assess lung magnetic resonance (MR) imaging with a respiratory-gated pointwise
encoding time reduction with radial acquisition (PETRA) sequence at 1.5 T and compare …

Lung morphology assessment of cystic fibrosis using MRI with ultra-short echo time at submillimeter spatial resolution

G Dournes, F Menut, J Macey, M Fayon, JF Chateil… - European …, 2016 - Springer
Objectives We hypothesized that non-contrast-enhanced PETRA (pointwise encoding time
reduction with radial acquisition) MR (magnetic resonance) sequencing could be an …

Real-life safety and effectiveness of lumacaftor–ivacaftor in patients with cystic fibrosis

…, M Abely, P Reix, C Marguet, J Macey… - American journal of …, 2020 - atsjournals.org
Rationale: Lumacaftor–ivacaftor is a CFTR (cystic fibrosis transmembrane conductance
regulator) modulator combination recently approved for patients with cystic fibrosis (CF) …

The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant

…, I Durieu, R Kanaan, J Macey… - European …, 2023 - Eur Respiratory Soc
Background The European Medicines Agency has approved the cystic fibrosis transmembrane
conductance regulator (CFTR) modulator combination elexacaftor/tezacaftor/ivacaftor (…

[HTML][HTML] Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease

…, L Bassinet, S Dominique, G Rault, J Macey… - Journal of Cystic …, 2017 - Elsevier
Objective To investigate the short-term adverse events and effectiveness of lumacaftor/ivacaftor
combination treatment in adults with cystic fibrosis (CF) and severe lung disease in a …

Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription

…, N Bouazza, B Chevalier, J Macey… - European …, 2023 - Eur Respiratory Soc
Background Around 20% of people with cystic fibrosis (pwCF) do not have access to the triple
combination elexacaftor/tezacaftor/ivacaftor (ETI) in Europe because they do not carry the …

[HTML][HTML] The clinical use of lung MRI in cystic fibrosis: what, now, how?

…, LL Walkup, I Benlala, MM Willmering, J Macey… - Chest, 2021 - Elsevier
To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF),
chest MRI has been historically out of the scope of routine clinical imaging due to technical …

3D ultrashort echo time MRI of the lung using stack‐of‐spirals and spherical k‐Space coverages: Evaluation in healthy volunteers and parenchymal diseases

…, E Blanchard, ME Truchetet, J Macey… - Journal of Magnetic …, 2018 - Wiley Online Library
Background Ultrashort echo time (UTE) has been shown to improve lung MRI quality in
three dimensions. The evaluation of 3D‐UTE stack‐of‐spirals VIBE (3D‐USV) sequence for …

Generating high-resolution synthetic CT from lung MRI with ultrashort echo times: initial evaluation in cystic fibrosis

…, I Benlala, B Denis de Senneville, T Benkert, J Macey… - Radiology, 2023 - pubs.rsna.org
Background Lung MRI with ultrashort echo times (UTEs) enables high-resolution and
radiation-free morphologic imaging; however, its image quality is still lower than that of CT. …